Budesonide, 1 X 500 mg (PHR1178-500MG)

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Budesonide is a nonsystemic glucocorticoid and an epimeric mixture, where both the epimers have similar anti-inflammatory activity. It is widely used in the treatment of Crohn′s disease. Budesonide may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using high-performance liquid chromatography technique. This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis. Budesonide is a second generation glucocorticoid with low systemic absorption. It is used as an anti-inflammatory agent in the treatment of asthma, rhinitis, and inflammatory bowel disease. It inhibits the expression of chemokine mRNA and production of eotaxin and RANTES protein in primary human bronchial epithelial cells. Budesonide is currently in clinical trials for the prevention of lung cancer. It shows inhibitory effects on benzo[a]pyrene-induced carcinogenesis of the lung in mice. These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available. To see an example of a Certificate of Analysis for this material enter LRAB3750 in the slot below. This is an example certificate only and may not be the lot that you receive.

Read Less